Article
The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients.
Cancer chemotherapy and pharmacology - 1 May 2012
Walko Christine M, Combest Austin J, Spasojevic Ivan, Yu Angela Y C, Bhushan Shriya, Hull J Heyward, Hoskins Janelle, Armstrong Delma, Carey Lisa, Collicio Frances, Dees E Claire
Abstract excerpt
PURPOSE: The prodrug cyclophosphamide is metabolized by cytochrome P450(CYP)2B6 to the active metabolite, 4-hydroxycyclophosphamide (4-OH), and by CYP3A4/5 to toxic chloracetaldehyde and 2-dechloroethylcyclophosphamide (DCE). Since aprepitant is a moderate inhibitor of CYP3A4, the study was designed to determine whether its concurrent use alters the pharmacokinetics (PK) of cyclophosphamide. In addition, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.